Aripiprazole for the treatment of irritability associated with autism

Bibliography

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition. American Psychiatric Association, Washington, DC; 2000
   Google Scholar
• Autism and developmental disabilities monitoring network surveillance year 2002. Principal investigators and centers for disease control and prevention. Prevalence of autism spectrum disorders – autism and developmental disabilities monitoring network, 14 sites, United States, 2002. MMQR Surveill Summ 2007;56:12-28
   Google Scholar
• Chakrabarti S, Fombonne E. Pervasive developmental disorders in preschool children: conformation of high prevalence. Am J Psychiatry 2005;162:1133-41
   PubMed Web of Science ®Google Scholar
• Fombonne E, Zakarian R, Bennett A, Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics 2006;118:e139-50
   PubMed Web of Science ®Google Scholar
• Lecavalier L. Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification. J Autism Dev Disord 2006;36:1101-14
   PubMed Web of Science ®Google Scholar
• Kanne M, Mazurek M. Aggression in children and adolescents with ASD: prevalence and risk factors. J Autism Dev Disord 2010: published online 20 October 2010, doi: 10.1007/s10803-010-1118-4
   Google Scholar
• Farmer C, Aman M. Aggressive behavior in a sample of children with autism spectrum disorders. Res Autism Spec Dis 2010;5:317-23
   Google Scholar
• Aman M, Lam K, Van Bourgondien M. Medication patterns in patients with autism: temporal, regional, and demographic influences. J Child Adolesc Psychopharmacol 2005;15:116-26
   PubMed Web of Science ®Google Scholar
• Janssen(Titusville, NJ). Risperidone [package insert]. July revision, 2009
   Google Scholar
• Otsuka Pharmaceutical Co., Ltd (Tokyo, Japan). Aripiprazole [package insert]. November revision, 2009
   Google Scholar
• Greenaway M, Elbe D. Focus on aripiprazole: a review of its use in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry 2009;18:250-260
   PubMed Web of Science ®Google Scholar
• Erickson C, Stigler K, Posey D, McDougle C. Aripiprazole in autism spectrum disorders and fragile X syndrome. Neurotherapeutics 2010;7:258-63
   PubMed Web of Science ®Google Scholar
• DeLeon A, Patel N, Crimson M. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 2004;26:649-66
   PubMed Web of Science ®Google Scholar
• Valicenti-McDermott M, Demb H. Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. J Child Adolesc Psychopharmacol 2006;16:549-60
   PubMed Web of Science ®Google Scholar
• Masi G, Cosenza A, Millepiedi S, Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: a retrospective study. CNS Drugs 2009;23:511-21
   PubMed Web of Science ®Google Scholar
• Stigler K, Posey D, McDougle C. Case report: aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adolesc Psychopharmacol 2004;14:455-63
   PubMed Web of Science ®Google Scholar
• Stigler K, Diener J, Kohn A, Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study. J Child Adolesc Psychopharmacol 2009;19:265-74
   PubMed Web of Science ®Google Scholar
• Aman M, Singh N. Aberrant behavior checklist manual. Slosson Educational Publications, East Aurora, NY; 1986
   Google Scholar
• Sparrow S, Cicchetti D, Balla D. Vineland Adaptive Behavior Scales. 2nd edition. Survey Interview Form/Caregiver Rating Form, Pearson Assessments, Linovia, MN; 2005
   Google Scholar
• Scahill L, Riddle M, McSwiggin-Hardin M, Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity. J Am Acad Child Adolesc Psychiatry 1997;36:844-52
   PubMed Web of Science ®Google Scholar
• Marcus R, Owen R, Kamen L, A double-blind, randomized, placebo-controlled study of fixed-dose aripiprazole in children and adolescents with autistic disorder. J Am Acad Child Adolesc Psychiatry 2009;48:1110-19
   PubMed Web of Science ®Google Scholar
• Owen R, Sikich L, Marcus R, Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 2009;124:1533-40
   PubMed Web of Science ®Google Scholar
• Aman M, Kasper W, Manos G, Line-item analysis of the Aberrant Behavior Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder. J Child Adolesc Psychopharmacol 2010;20:415-22
   PubMed Web of Science ®Google Scholar
• Findling R, Marcus R, Kamen L, 52-week open-label study of the safety and tolerability of aripiprazole flexibly dosed in the treatment of irritability in children and adolescents with autistic disorder. Poster presented at the 48th Annual Meeting of the American College of Neuropsychopharmacology; December 6-10, 2009; Hollywood, FL, USA
   Google Scholar
• Robb A, Anderson C, Bellocchio E, Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects. Prim Care Companion J Clin Psychiatry, in press
   Google Scholar
• McCollough M, Owen R, Corey-Lisle P, A 52-week safety and tolerability study of aripiprazole for the treatment of irritability in pediatric patients (6 – 17 years) with autistic disorder. Poster presented at the 163rd Annual Meeting of the American Psychiatric Association; May 22-26, 2010; New Orleans, LA, USA
   Google Scholar
• Aman M, Vinks A, Remmerie B, Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. Clin Ther 2007;29:1476-86
   PubMed Web of Science ®Google Scholar
• Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. New Engl J Med 2002;347:314-21
   PubMed Web of Science ®Google Scholar